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1. INTRODUCTION {#ame212004-sec-0005}
===============

Diabetes mellitus (DM) is prevalent worldwide, and according to World Health Organization (WHO) and the American Diabetes Association diagnostic criteria, 439 million adults will be affected by diabetes by 2030.[1](#ame212004-bib-0001){ref-type="ref"} DM is characterized by a relative or absolute lack of insulin, which may lead to hyperglycemia. The two main types of DM are type 1 DM (T1DM) and type 2 DM (T2DM). T1DM is an autoimmune disease that leads to the destruction of the insulin‐producing pancreatic β‐cells in the islets, and it is most commonly diagnosed in children and young adults. T2DM is a complex, heterogeneous, and polygenic disease characterized mainly by insulin resistance and pancreatic β‐cell dysfunction. It is the most common type of diabetes, and the percentage rate is 90% of all incidences DM.[2](#ame212004-bib-0002){ref-type="ref"}, [3](#ame212004-bib-0003){ref-type="ref"} Some data indicate that high‐fat diet (HFD) and obesity are the main risk factors for T2DM.[4](#ame212004-bib-0004){ref-type="ref"} Therefore, in theory, weight reduction and exercise should improve the T2DM state, but in reality, lifestyle interventions have failed in numerous cases. Therefore, drugs must be used in these T2DM cases to avoid the deleterious effects of chronic hyperglycemia. Currently, T2DM drug treatments mainly include chemical drugs such as biguanides, thiazolidinediones, sulfonylureas, [d]{.smallcaps}‐phenylalanine, meglitinides, and α‐glucosidase inhibitors in addition to insulin. All these drugs have different degrees and types of side effects[5](#ame212004-bib-0005){ref-type="ref"}, [6](#ame212004-bib-0006){ref-type="ref"}; therefore, there is a demand for new safer compounds for the treatment of diabetes. Because of the apparent minimal side effects, natural products have attracted the attention of scientists.

Fenugreek (*Trigonella foenum‐graecum* L), a well‐known annual herb belonging to the family Leguminosae, has been widely used as a spice, edible vegetable, and medicinal plant for a long time. Furthermore, some studies have reported on the active components of fenugreek.[7](#ame212004-bib-0007){ref-type="ref"}, [8](#ame212004-bib-0008){ref-type="ref"}, [9](#ame212004-bib-0009){ref-type="ref"}, [10](#ame212004-bib-0010){ref-type="ref"}, [11](#ame212004-bib-0011){ref-type="ref"} 4‐Hydroxyisoleucine and galactomannan, isolated from fenugreek, can lower the blood glucose levels and improve lipid metabolism in vivo.[12](#ame212004-bib-0012){ref-type="ref"} Other studies have suggested that fenugreek might possess antihypoglycemic and antihyperlipidemic effects in humans and animal models.[13](#ame212004-bib-0013){ref-type="ref"}, [14](#ame212004-bib-0014){ref-type="ref"}, [15](#ame212004-bib-0015){ref-type="ref"}, [16](#ame212004-bib-0016){ref-type="ref"}, [17](#ame212004-bib-0017){ref-type="ref"}, [18](#ame212004-bib-0018){ref-type="ref"}, [19](#ame212004-bib-0019){ref-type="ref"}, [20](#ame212004-bib-0020){ref-type="ref"}, [21](#ame212004-bib-0021){ref-type="ref"}, [22](#ame212004-bib-0022){ref-type="ref"}, [23](#ame212004-bib-0023){ref-type="ref"} The mechanism of antihypoglycemia induced by fenugreek seed extract was shown to be mediated through stimulation of an insulin signaling pathway in a research study.[17](#ame212004-bib-0017){ref-type="ref"}

2. MATERIALS AND METHODS {#ame212004-sec-0006}
========================

2.1. Preparation of fenugreek {#ame212004-sec-0007}
-----------------------------

Fenugreek was collected from Qinghai Province of the PR of China, where Chinese herbal medicine is abundant. The purified fenugreek extract was obtained from Northwest Institute of Plateau Biology, Chinese Academy of Sciences in December 2015. Dried fenugreek seeds (500 g) were ground into a powder and sequentially extracted thrice with 75% ethanol (10 L) under reflux at 60°C. After vacuum concentration, 245 g of the residues was diluted with water (1 L) and further successively extracted with light petroleum (boiling point 60‐90°C, 2.0 L), ethyl acetate (2 L), and *n*‐butanol (3 L). Each solution was vacuum evaporated to dryness at 60°C to obtain a total yield of 30.5, 33.7, and 35 g of petroleum ether, ethyl acetate (flavonoid), and *n*‐butanol (stilbene glycoside) extracts, respectively.

2.2. Study design {#ame212004-sec-0008}
-----------------

Male C57BL/6J mice (n = 100, Vital River Laboratory Animal Technology Co., Ltd., Beijing, China) weighing 18‐22 g (4 weeks age) were purchased and maintained at 5 animals per IVC cage at a stable temperature (22‐23°C) and humidity (60%), with a 12‐h light‐dark cycle in the Laboratory Animal Center Chinese Center for Diseases control and Prevention, Beijing. The animal had free access to water and food. After acclimation for 1 week, the mice were fed HFD (the ingredients were consistent with the D12492 diet) except for the uninduced control. Then, 5 weeks later, they were injected with STZ to induce T2DM, and 72 h later, the fasting blood glucose (FBG) was measured. Mice with FBG levels ≥ 11 mmol/L were considered hyperglycemic in our study. According to the blood glucose level, 60 mice were randomly divided into the following 6 groups: positive control (PC), T2DM animal model (M), flavonoid high and low doses (E1H and E1L, respectively), and stilbene glycoside high and low doses (E2H and E2L, respectively). Fenugreek extracts at doses of 20 and 80 mg kg^−1^ d^−1^ were intragastric administrated to the EH and EL groups, respectively, for 4 weeks. Metformin (500 mg kg^−1^ d^−1^) was used as a positive control.

The FBG of the mice was tested weekly, and at the end of week 4 after intragastric administration of the test substances, the antioxidant and pathological indexes were assayed. This study was approved and supervised by the Laboratory Animal Welfare and Ethics Committee in China CDC (permission no. 2016‐CCDC‐WER‐002).

2.3. Measurement of serum parameters {#ame212004-sec-0009}
------------------------------------

After 4 weeks of fenugreek extract treatment, the mice were fasted overnight, and blood samples were drawn from the tail tip to determine the FBG using a glucose meter. Then, more blood samples were obtained from the orbital venous plexus for serum parameter analysis. The serum concentrations of glucose, malondialdehyde (MDA), superoxide dismutase (SOD), and catalase (CAT) were determined using a spectrophotometer (Spectra MRTM, Dynex Technologies, Chantilly, Virginia, USA) and commercial assay kits (Nanjing Jian Cheng Biology Co., Nanjing, China).

2.4. Pathological indexes {#ame212004-sec-0010}
-------------------------

After blood collection, the mice were dissected after euthanasia, and the liver, pancreas, and kidney were fixed in 10% formalin buffer for the pathological indexes determination, which was conducted by the College of Veterinary Medicine, China Agricultural University.

2.5. Statistical analyses {#ame212004-sec-0011}
-------------------------

The data were expressed as means ± standard error of the mean (SEM). The statistical package for the social sciences ([spss]{.smallcaps}) for Windows version 19 (IBM Corp., Armonk, NY, USA) was used for the statistical analysis. The Mann‐Whitney U and Kruskal‐Wallis tests were performed. The results of the nonparametric comparisons were considered statistically significant at *P *\< .05.

3. RESULTS {#ame212004-sec-0012}
==========

3.1. Two main effective constituents of fenugreek {#ame212004-sec-0013}
-------------------------------------------------

The high‐performance liquid chromatography (HPLC) product analysis chromatogram is shown in Figure [1](#ame212004-fig-0001){ref-type="fig"}. All the above experiments were performed at the Northwest Institute of Plateau Biology, Chinese Academy of Sciences.

![High‐performance liquid chromatography (HPLC) product chromatograms. A, Three standard substance (flavonoids), orientin (retention time \[RT\] = 10 min), vitexin (RT = 12 min), and isovitexin (RT = 14 min). B, Three standard substance (stilbene glycosides), rhaponticin (RT = 13 min), deoxyrhapontin (RT = 20 min), and leaves simple emodin (RT = 23 min). C, Fenugreek ethyl acetate extract. D, Fenugreek 30% *n*‐butyl alcohol extracts](AME2-1-68-g001){#ame212004-fig-0001}

3.2. Blood glucose level and weight {#ame212004-sec-0014}
-----------------------------------

After the STZ injection, the blood glucose level and weight were measured once a week. The body weight declined by week 4 for the M, PC, E1H, E1L, E2H, and E2L groups was 17.1%, 20.8%, 14.4%, 15.9%, 11.2%, and 11.3%, respectively, compared to the weight at week 1 (Table [1](#ame212004-tbl-0001){ref-type="table"}). The body weight and blood glucose level were measured on the same day. The M group displayed a glucose level of 17.92 ± 0.97 mmol/L g at week 1, which was almost invariant up to week 4 when it was 17.68 ± 3.69 mmol/L. In contrast, the glucose level was significantly (*P *\< .01) reduced at 19.2%, and 36.5% by week 4 in the E1H and E2H group compared to their respective values at week 1 (Table [2](#ame212004-tbl-0002){ref-type="table"}).

###### 

Change in weight of type 2 diabetes mellitus (T2DM) mouse model

  Group/Week   Weight (g)                                   
  ------------ -------------- -------------- -------------- --------------
  M Gr.        21.00 ± 5.00   18.20 ± 3.70   19.00 ± 2.74   17.40 ± 2.97
  PC Gr.       25.83 ± 2.83   24.00 ± 2.00   23.67 ± 2.25   22.83 ± 2.93
  E1H Gr.      25.00 ± 5.10   22.00 ± 4.69   21.60 ± 3.51   21.40 ± 4.72
  E1L Gr.      26.40 ± 4.51   22.20 ± 3.56   22.00 ± 3.81   22.20 ± 5.07
  E2H Gr.      23.20 ± 3.63   21.00 ± 2.33   21.40 ± 2.07   20.60 ± 3.29
  E2L Gr.      23.00 ± 3.16   21.8 ± 3.77    22.20 ± 3.42   20.40 ± 6.02

n = 10; M, T2DM model; PC, positive control; E1H and E1L, flavonoid high and low doses, respectively; E2H and E2L, stilbene glycoside high and low doses, respectively.

John Wiley & Sons, Ltd

###### 

Change in blood glucose level of type 2 diabetes mellitus (T2DM) mouse model

        Blood glucose level (mmol/L)                                                                                                                 
  ----- ------------------------------ ------------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------
  M     17.92 ± 0.97                   17.12 ± 3.57                                           16.82 ± 3.67                                           17.68 ± 3.69
  PC    15.00 ± 4.30                   16.50 ± 4.95                                           10.00 ± 5.05[a](#ame212004-note-0005){ref-type="fn"}   10.75 ± 4.35[a](#ame212004-note-0005){ref-type="fn"}
  E1H   16.50 ± 6.03                   16.25 ± 5.38                                           13.67 ± 3.06[a](#ame212004-note-0005){ref-type="fn"}   13.33 ± 6.43[a](#ame212004-note-0005){ref-type="fn"}
  E1L   16.20 ± 3.70                   15.60 ± 4.83                                           16.00 ± 3.16[b](#ame212004-note-0006){ref-type="fn"}   16.50 ± 7.93
  E2H   17.33 ± 1.53                   13.33 ± 4.04[a](#ame212004-note-0005){ref-type="fn"}   13.33 ± 2.08[a](#ame212004-note-0005){ref-type="fn"}   11.00 ± 1.60[a](#ame212004-note-0005){ref-type="fn"}
  E2L   17.00 ± 3.00                   18.40 ± 1.95                                           16.00 ± 2.55[b](#ame212004-note-0006){ref-type="fn"}   16.20 ± 5.76[b](#ame212004-note-0006){ref-type="fn"}

n = 10; M, T2DM model; PC, positive control; E1H and E1L, flavonoid high and low doses, respectively; E2H and E2L, stilbene glycoside high and low doses, respectively.

*P* \< .01 compared with week 1 value of respective group.

*P* \< .05 compared with week 1 value of respective group.

John Wiley & Sons, Ltd

3.3. Estimation of SOD and CAT activity {#ame212004-sec-0015}
---------------------------------------

The serum SOD activity declined in the M group and ameliorated in E1H and E2H groups compared with that in the normal group. The increase in SOD activity of the E1H and E2H groups was 27.6% and 25.0%, respectively (Table [3](#ame212004-tbl-0003){ref-type="table"}) compared to that of the model group (*P *\< .01) and similar results were obtained with the CAT activity analysis. The increase in CAT activity of the E1H and E2H groups was 39.0% and 40.6%, respectively (Table [3](#ame212004-tbl-0003){ref-type="table"}) compared to the model group (*P *\< .01).

###### 

Change in serum antioxidant levels of type 2 diabetes mellitus (T2DM) mouse model

  Group/Index   SOD (IU/mL)                                            MDA (nM/mL)                                           CAT (IU/mL)
  ------------- ------------------------------------------------------ ----------------------------------------------------- ------------------------------------------------------
  Normal        98.43 ± 9.03                                           4.75 ± 0.35                                           68.42 ± 9.15
  M             69.66 ± 3.93[a](#ame212004-note-0007){ref-type="fn"}   12.57 ± 1.0                                           37.17 ± 7.21[a](#ame212004-note-0007){ref-type="fn"}
  PC            89.51 ± 2.06[b](#ame212004-note-0008){ref-type="fn"}   7.41 ± 0.95[b](#ame212004-note-0008){ref-type="fn"}   59.81 ± 9.60[b](#ame212004-note-0008){ref-type="fn"}
  E1H           88.86 ± 2.74[b](#ame212004-note-0008){ref-type="fn"}   7.80 ± 1.16[b](#ame212004-note-0008){ref-type="fn"}   51.67 ± 8.61[b](#ame212004-note-0008){ref-type="fn"}
  E1L           62.44 ± 8.47                                           9.83 ± 1.04                                           45.05 ± 8.60
  E2H           87.08 ± 6.54[b](#ame212004-note-0008){ref-type="fn"}   7.97 ± 1.24[b](#ame212004-note-0008){ref-type="fn"}   52.25 ± 4.30[b](#ame212004-note-0008){ref-type="fn"}
  E2L           69.21 ± 1.38                                           7.74 ± 1.21[b](#ame212004-note-0008){ref-type="fn"}   44.62 ± 6.28

*P* \< .01, compared with normal group.

*P* \< .01 compared with M group; n = 10; M, T2DM model; PC, positive control; E1H and E1L, flavonoid high and low doses, respectively; E2H and E2L, stilbene glycoside high and low doses, respectively.

John Wiley & Sons, Ltd

3.4. Measurement of lipid peroxidation {#ame212004-sec-0016}
--------------------------------------

The serum MDA level was increased significantly in the M group compared to the Normal group. After administration of the fenugreek extracts, the serum MDA decreased especially in the E1H, E2H, and E2L groups. Furthermore, the percentage decrease in the MDA contents was 37.9%, 36.6%, and 38.4%, respectively, compared to the M group (Table [3](#ame212004-tbl-0003){ref-type="table"}).

3.5. Histopathology of kidney, liver, and pancreas {#ame212004-sec-0017}
--------------------------------------------------

The histopathological evaluation of the kidney, pancreas, and liver tissues from the control, T2DM, and fenugreek extract‐treated groups revealed obvious fatty degeneration of liver and kidney in the T2DM group. An increased number of vacuolated cells occurred in the liver and kidney tissues. The volume of the islet varied in size and fatty infiltration occurred in the T2DM group. In contrast, the degree of fatty degeneration was improved in the fenugreek extract‐treated groups, especially the E2H group, as shown in Table [4](#ame212004-tbl-0004){ref-type="table"} and Figure[2](#ame212004-fig-0002){ref-type="fig"}.

###### 

Fatty degeneration of liver and kidney

  Group                          Blank   M   E1L   E1H   E2L   E2H                           
  ------------------------------ ------- --- ----- ----- ----- ----- ---- ---- --- ---- ---- ----
  No.                            1       2   3     4     5     6     7    8    9   10   11   12
  Fatty degeneration in liver    N       N   +++   +++   N     N     \+   N    N   \+   N+   N
  Fatty degeneration in kidney   N       N   +++   ++    \+    N     \+   \+   N   \+   N    N

N, no abnormity; +, slight lesioning; ++, no remarkable lesioning; +++, remarkable lesioning. M, T2DM model; E1H and E1L, flavonoid high and low doses, respectively; E2H and E2L, stilbene glycoside high and low doses, respectively.

John Wiley & Sons, Ltd

![Histopathological changes in kidney, liver, and pancreas tissues stained with hematoxylin and eosin (H&E, ×200)](AME2-1-68-g002){#ame212004-fig-0002}

4. DISCUSSION {#ame212004-sec-0018}
=============

Previous studies have indicated that C57BL/6J mice are more liable to show an increase in body weight after feeding HFD, and they carry a genetic predisposition to developing T2DM.[24](#ame212004-bib-0024){ref-type="ref"}, [25](#ame212004-bib-0025){ref-type="ref"} STZ was initially isolated from *Streptomyces achromogenes* in 1960, but its diabetogenic properties were not described until 1963.[26](#ame212004-bib-0026){ref-type="ref"} Furthermore, a subsequent study indicated that the diabetogenic effects were due to selective destruction of the pancreatic islet β cells.[27](#ame212004-bib-0027){ref-type="ref"} In recent years, numerous researchers have used HFD and STZ‐treated rodents as T2DM animal models.[2](#ame212004-bib-0002){ref-type="ref"}, [28](#ame212004-bib-0028){ref-type="ref"}, [29](#ame212004-bib-0029){ref-type="ref"} The HFD can induce insulin resistance, glucose intolerance, or both, and this may mimic the human lifestyle.

In addition, STZ can shorten the time required to establish the model and improve the response of model animals. Moreover, the known characteristics of the HFD/STZ rodent model have been reviewed and compared with the pathophysiology of human T2DM.[30](#ame212004-bib-0030){ref-type="ref"} In our study, we verified that T2DM could be induced successfully by administering an HFD and STZ (100 mg/kg) injected into C57BL/6J mice. Table [1](#ame212004-tbl-0001){ref-type="table"} shows that the blood glucose was maintained at a high level and the body weight continued to decline in the M group during the period of our study. These characteristics are in accordance with human T2DM.

In contrast, the blood glucose reduced gradually, and the weight declined slightly or remained relatively stable in the groups intragastrically administered the fenugreek extracts. Furthermore, after a 4‐week treatment, the blood glucose level was obviously lower than it was at the beginning of treatment and the effect was obviously dose‐dependent. There was a significant difference between the M and E2H groups, indicating that the E2 extracts likely had more potent effects on the hyperglycemic T2DM animal model than the other treatments did.

Currently, increasing evidence indicates that reactive oxygen species (ROS) play an important role in the developmental process of DM and its complications.[31](#ame212004-bib-0031){ref-type="ref"} Numerous clinical cases have also shown that a close association exists between the progression of DM and oxidative stress, which promotes the DM process when ROS levels increase or oxidative damage occurs.[32](#ame212004-bib-0032){ref-type="ref"} Free radicals can cause polyunsaturated fatty acid peroxidation and the final product, MDA, can generate protein, nucleic acid, and lipid cross‐linking, and biological membrane denaturation, as well as cell mutation, aging, and death. The MDA level reflects the degree of lipid peroxidation in vivo, and indirectly reflects the degree of cell damage.[33](#ame212004-bib-0033){ref-type="ref"} The SOD enzyme can eliminate free radicals directly, interdict chain reactions of the free radicals, and then protect the cells against destruction by these processes.[34](#ame212004-bib-0034){ref-type="ref"}

By reacting with hydrogen peroxide (H~2~O~2~), glutathione (GSH) can maintain the structural integrity of the cell membrane. Low levels or depletion of GSH induces numerous chemical substances or aggravates the effects of toxic environmental factors. This may be related to the increase in oxidative damage. Therefore, the level of GSH is an important factor for measuring the antioxidant ability of an organism. In our study, we observed a remarkable increase in serum MDA levels of the M group mice, with a decline in the SOD activity. These results indicate that the increase in free radical levels enhanced the lipid peroxidation in the body of M group mice. This reflected the declining antioxidant ability of the body. In contrast, the E1H‐ and E2H‐treated groups showed adverse effects. The amount of MDA was decreased while the SOD and CAT activity increased compared to that of the M group. All the results indicate that fenugreek extracts may improve SOD activity, clear oxygen radicals, and inhibit lipid peroxidation in the body. Especially, administration of the high dose of the extracts induced significant effects on these indexes.

The histopathological changes in the kidney, liver, and pancreas tissues indicated that there was serious fatty degeneration of the kidneys and livers of the M group mice. In contrast, no abnormal changes were observed in the blank control group. The groups administered fenugreek extracts showed an improvement in the degree of fatty degeneration.

The size of islet cells in the M group was considerably different from that of the other groups. The islets in the blank control group were obviously smaller than those in the M group, and the same effect was observed with the number of islets.

5. CONCLUSION {#ame212004-sec-0019}
=============

The results revealed that this animal model of T2DM was successfully established and suitable for this study. The comparison of the antioxidant indexes (SOD, MDA, and CAT) of the mice in the M group and those cured by treatment with the fenugreek extracts revealed that flavonoids and stilbene glycosides were the two main active components that mediated the antidiabetic effects in the T2DM mice model.
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